Common medications trigger Alzheimer's, researchers find

Share this article:


Certain widely prescribed medications can trigger or slow the progress of Alzheimer's disease, according to recently published research.
 
A Mount Sinai Medical Center team screened 1,600 FDA-approved medications, using a computer algorithm to determine which drugs are associated with blocking or stimulating beta amyloid accumulation. Amyloid plaques build up in the brains of Alzheimer's patients.
 
 
Of the screened drugs, 800 reduced amyloid beta content more than 10% in primary neurons from mice, the researchers found. About 240 drugs promoted amyloid beta. 
 
While many classes of drugs were found to impact amyloid beta production, the researchers focused especially on those used to treat cardiovascular conditions. Certain blood pressure medications, such as propranolol (Inderal) and nicardipine (Cardene), reduced amyloid beta production, while drugs including furosemide (Lasix) had the opposite effect. Experiments with mice confirmed that some CV medications, particularly carvedilol (Coreg), hold promise as Alzheimer's drugs.
 

“This line of investigation will lead to the identification of common medications that are potentially beneficial or detrimental to [Alzheimer's disease] as a reference for physicians to consider when prescribing the most appropriate drugs for their patients, particularly for treating chronic disorders among the growing geriatric population,” the researchers wrote.

 
The complete findings were published online in the journal PLoS One .
Share this article:

More in News

Long-term care continues to lead in deal volume and value: PwC report

Long-term care continues to lead in deal volume ...

Long-term care bucked healthcare industry trends with strong merger and acquisition activity in the second quarter of 2014, according to newly released data from professional services firm PricewaterhouseCoopers.

Empowering nurse practitioners could reduce hospitalizations from SNFs, study finds

Granting more authority to nurse practitioners is associated with reduced hospitalization of skilled nursing facility residents, according to recently published findings.

Pioneer ACO drops out of program, despite reductions in skilled nursing utilization

A California healthcare system has become the latest dropout from the Pioneer Accountable Care Organization program, despite reducing skilled nursing facility utilization and improving its readmission rates. Sharp HealthCare announced its decision in a quarterly financial statement released Tuesday.